156: Once-daily intravenous busulfan versus oral busulfan in children prior to stem cell transplantation Study of pharmacokinetics and clinical outcomes by Boelens, J.J. et al.
PEDIATRIC DISORDERS
154
ALLOGENEIC TRANSPLANTATION FOR WISKOTT ALDRICH SYNDROME
USING A REDUCED INTENSITY CONDITIONING REGIMEN
Barnes, Y.J.1, Hayashi, R.J.2, Witty, S.2, Shenoy, S.2 1St. Louis Chil-
dren’s Hospital, Saint Louis, MO; 2Washington University School of
Medicine Pediatric Hematology/Oncology, Saint Louis, MO.
Background: Allogeneic stem cell transplantation (SCT) is
curative for Wiskott Aldrich syndrome (WAS), an X-linked
disorder with thrombocytopenia, immune deﬁciency, and sus-
ceptibility to malignancy/autoimmunity. Standard myeloabla-
tive conditioning regimen for SCT often result in lasting tox-
icities. Hence, we used reduced intensity conditioning (RIT) in
2 patients whose disease manifestations included infections and
hemorrhage.
Methods: The 2 males (R1 and R2), 7 and 8 months old,
underwent SCT with bone marrow from a HLA identical sibling
and 10/10 allele matched unrelated donor respectively. Condi-
tioning consisted of 23 and 28 mg of Campath-1H (targeted
dose was 33 mg) on days -22 and -19, ﬂudarabine (1.0 mg/kg/
day) on day -8 to -4, and melphalan (4.7 mg/kg) on day -3.
GVHD prophylaxis included cyclosporine, short course meth-
otrexate, and methylprednisolone. GCSF was administered until
neutrophil engraftment.
Results: Campath-1H was associated with vasculitic edema
and blisters in R1 resulting in lowered dosing. R2 received a
lower dose following an unrelated aspiration episode. Neutro-
phils engrafted (ANC 500/dl) on days 15 and 12; platelets
engrafted (20,000/dl) on days 70 and 13 respectively. Neither
developed grade 2 GVHD or severe organ toxicity. R1 is off
immunosuppression and R2 is on a cyclosporine taper. By mo-
lecular analysis 9 months post SCT, R1 has 81% lymphoid and
22% myeloid; R2 has 100% lymphoid and 65% myeloid donor
chimerism that is stable post immunosuppression taper. R2
developed autoimmune hemolytic anemia that responded to
rituximab therapy. Neither had bleeding complications. Lym-
phocyte subpopulations and function were recovering 6 months
post SCT.
Conclusions: This reduced intensity conditioning achieved
mixed donor chimerism in 2 patients with WAS, resulting in
transfusion independence and amelioration of bleeding compli-
cations. SCT was not associated with signiﬁcant organ toxicity
or GVHD. Monitoring for durability of engraftment and other
transplant related complications is in progress. A reduced in-
tensity transplant that allows stable donor engraftment and
limits chemotherapy may spare young patients toxicities of stan-
dard conditioning and merits further investigation.
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CHARACTERISTICS OF THE PEDIATRIC BLOOD AND MARROW TRANS-
PLANT ADVANCED PRACTICE NURSE
Barnes, Y.J.1, Fisher, V.L.2, Olson, E.3, PBMTC Nursing Discipline4
1St. Louis Children’s Hospital, Saint Louis, MO; 2Rainbow Babies and
Children’s Hospital, Cleveland, OH; 3Children’s Health Care of At-
lanta, Atlanta, GA; 4Pediatric Blood and Marrow Transplant Consor-
tium Nursing Discipline.
Purpose: This survey was designed to identify the demographics
and professional responsibilities of a Pediatric Advanced Practice
Nurse (APN) in the ﬁeld of Blood & Marrow Transplantation
(BMT) within the Pediatric Blood & Marrow Transplant Consor-
tium (PBMTC).
Methods: A survey was sent to nurses within institutions that
participate in the PBMTC. The survey was designed to collect
information about personal and institutional demographics, trans-
plant speciﬁc responsibilities and procedures.
Results: Thirty-one surveys were returned representing re-
sponses from various institutions. Demographic characteristics of
the APN are reported in Table 1. All APN’s report performing
both autologus and allogeneic transplants. Eight-three percent are
individual pediatric transplant programs with 75% of them aca-
demic centers 201 beds. The majority of all centers are FACT
(Foundation of Accreditation for the Cellular Therapy) accredited,
CIBMTR reporting centers & research centers. Sixty-two percent
report an individual designated for quality assurance. Approxi-
mately half of these institutions have a designated program man-
ager. The predominant APN responsibilities include the following:
initial consults (58%), initial H & P (41%), communicate with
referring centers (74%), initial contact for complications (45%),
daily patient rounds (62%), consulted for BMT pts in PICU
(58%), and 75% are involved in clinical decision making on patient
care. The predominant APN tasks are orders pre BMT evaluation
62%, prescribes admission orders 50%, performs Bone Marrow
aspirate/biopsy 41%, lumbar punctures 33%, infuses stem cells
45%, harvest 50%, manages drug levels 62%, provides discharge
education 70%, organizes home care set up and writes discharge
orders/prescriptions 50%, & formulates post-BMT follow up plan
70%. The support staff at institutions includes 1-2 physicians
(41%), 1-2 nurse practitioners (45%), nurse coordinators (87%),
1-2 data managers (79%), and all have a search coordinator. The
median salary ranges from $70,000 -$79,000 with 87% employed
full time. Ninety-one percent of respondents identiﬁed attending
outside institutional meetings and generating research based nurs-
ing projects.
Conclusion: Based on the submitted surveys the PBMTC APN
is a highly experienced and motivated nurse who has multiple
responsibilities over the transplant trajectory. Support for this
PBMTC APN deserves further attention related to the vast re-
sponsibilities these individuals perform.
Table 1 Demographic Data
Demographics Results
Age 40 - 45 yrs
Sex Female  100%
Averge years as
RN
> 16 yrs  58%
Averge years as
APN
6 - 10 yrs  25% , >11yrs 38%
Highest degree MSN  70%
Job title Nurse Practitioner  37%, Nurse
Coordinator  41%, Clinical
Nurse Specialist  16%
Practice Area Both in-patient & outpatient care
areas  83%
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ONCE-DAILY INTRAVENOUS BUSULFAN VERSUS ORAL BUSULFAN IN
CHILDREN PRIOR TO STEM CELL TRANSPLANTATION: STUDY OF
PHARMACOKINETICS AND CLINICAL OUTCOMES
Boelens, J.J.1, Bartelink, I.2, Bredius, R.3, Zwaveling, J.4,
Bierings, M.1, Rademaker, K.2, Ververs, T.2, Kesteren, C. van2
1UMCU/WKZ: Dept. Haematology/Immunology/BMT, Utrecht,
Netherlands; 2UMCU: Dept. Clinical Pharmacy, Utrecht, Netherlands;
3LUMC: Dept. of Heamatology/Immunology/BMT, Leiden, Nether-
lands; 4LUMC: Dept. of Clinical Pharmacy, Leiden, Netherlands.
Background: Dose targeting (IV or oral) of busulfan has been
suggested to be associated with higher “alive and engrafted” (A&E)
rates due to less graft-failure and lower toxicity. Busulfan is usually
given in 4 doses. In this study we compared the outcome of
haematopoietic stem cell transplantation (SCT) between once daily
IV dose-targeted busulfan (IVdtBU: based on therapeutic drug
monitoring (TDM)) and current practice of un-targeted oral
busulfan (POBU) and we studied the feasibility of TDM of busul-
fan in clinical practice.
Methods: Since 2003 IVdtBU was introduced gradually: at ﬁrst
only in pts receiving an SCT for an “inborn error of metabolism”,
followed by immunodeﬁciency pts and malignancies. Busulfan was
part of a myeloablative regimen. Serotherapy was given in case of
an unrelated donor. Pts received a 3-hour infusion of busulfan at a
ﬁrst dose of 120mg/m2 (1year) or 80mg/m2 (1year), or POBU
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16mg/kg/day. The target area under the curve (AUC) was deﬁned
as 17.500 g*h/l and was assessed on day 1 and day 4 based on 3
blood samples. Dose adjustment was performed before the second
dose. Primary endpoint was A&E, secondary endpoints were veno-
occlusive disease (VOD), graft versus host disease (GvHD). A risk
factor analyses was performed using logistic regression.
Results: Between 6/2003 and 6/2006 60 pts were included (30
IVdtBU and 30 POBU). The IVdtBU and POBU groups were
comparable regarding age, sexe, indication for SCT, match-grade
and donor-source. The A&E rates for the IVdtBU and POBU
were 83.3% and 40%, respectively (OR 7.3; 95% CI 2,1-26;
p0.002). VOD occurred in 33% and 13% of patients, respectively
(P0,1). No difference in GvHD (grade2) was found. Average
AUC after the ﬁrst dose was 20.710 g*h/l and decreased after
targeting to 18.920 g*h/l. However, interpatient variation re-
mained comparable. The pharmacokinetic data showed a large
difference between the clearances of busulfan in children as com-
pared to adults. Clearance correlated well to body surface area and
seemed to be constant at all ages, whereas clearance divided to
bodyweight decreased as a function of age.
Conclusions: IVdtBU resulted in higher A&E rates compared to
POBU. A non-signiﬁcantly trend to more VOD in the IVdtBU
group was observed. Because of the generally high AUC of day 1
starting dose might be lowered. Once daily dosing of IV busulfan
with TDM was feasible in routine clinical practice and improved
the A&E rates for SCT in children.
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OUTCOMES OF CORD BLOOD TRANSPLANTATION FOR HURLER’S SYN-
DROME. AN EUROCORD-WORKING PARTY INBORN ERRORS EBMT
SURVEY
Boelens, J.J.1, Bierings, M.1, Wynn, R.2, O’Meara, A.3, Veys, P.4,
Bertrand, Y.5, Wraith, E.2, Cavazzana-Calvo, M.6, Wulffraat, N.1,
Gluckman, E.7, Rocha, V.7 1UMCU/WKZ: Dept. Heamatology/Immu-
nology/BMT, Utrecht, Netherlands; 2Royal Manchester Children’s Hos-
pital, Manchester, United Kingdom; 3Our Lady’s Hospital for Sick
Children, Dublin, Ireland; 4Great Ormond Street Hospital, London,
United Kingdom; 5Debrousse Hospital, Lyon, France; 6Hopital Necker-
Enfants Malades, Paris, France; 7Saint Louis Hospital/EUROCORD,
Paris, France.
Background: Hurler’s syndrome (HS), the most severe form of
mucopolysaccharidosis type-I causes progressive deterioration of
the central nervous system and death in childhood. Allogeneic-
stem cell transplantation (SCT) before the age of two years halts
disease progression and prolongs life. Graft-failure and mixed
chimerism limits the success of SCT for HS. (Unrelated) cord
blood grafts are suggested to be a good alternative source for bone
marrow.
Methods: Patient registered to EUROCORD-database and
EBMT-Hurler syndrome database were included. Between 1991
and 2004 forty-two patients received an (unrelated)-cord blood
transplant. The children were evaluated for engraftment, adverse
event and effects on disease symptoms. A risk factor analyses was
performed using logistic regression.
Results: From 40 patients enough data was available. After a
median follow up period of 14 (7-84) mths the “alive and en-
grafted” rate was 69% after ﬁrst SCT. Donors used were: 4 HLA-
identical family and 36 unrelated cord blood (23 mismatched: 18
5/6-matched and ﬁve 4/6-matched). With the exception of 2, all
patients received a myeloablative conditioning regimen. Cell dose
used was median 7.9 (1.5-32) *107 NC/kg and 2,6 (0,7-25) *105
CD34/Kg. In multivariate logistic regression analyses, year of
transplantation (2000 vs. 2001: A&E 40 vs 84%: OR 7,5 range
1,7-30, p0.007) and NC-dose of less than 5*107 NC/kg (OR 6,4,
range 1,7-39: p 0.045) were found to be risk factors for graft-
failure. Only 2 of the 27 patients A&E patients showed a mixed
chimerism (86 and 92%: still increasing). All patients had normal
enzyme levels. Acute-GvHD (grade1) was observed in 15%,
while chronic-GvHD was seen in 19% (extensive 8%) of patients
at risk. SCT improved somatic features of HS.
Conclusion: Outcome following cord blood SCT for Hurler’s
syndrome is encouraging. (U)CB is a good alternative stem cell
source and might even be preferential since cord-blood appeared
to increase the likelihood of sustained engraftment resulting in
full-donor chimerism and normal enzyme levels.
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CLINICAL OUTCOME OF HUMAN HERPES-6 REACTIVATION AFTER
HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN
Pagter, A. de1, Sanders, L.1, Rossen, J.2, Schuurman, R.2, Wolfs, T.1,
Versluys, B.1, Boelens, J.J.1 1UMCU/WKZ: Dept. of Haematology/
Immunology/BMT, Utrecht, Netherlands; 2UMCU: Dept. of Virology,
Utrecht, Netherlands.
Background: Although human herpes virus 6 (HHV6) is known
to reactivate during haematopoietic cell transplantation (HCT)
and is suggested to be associated with severe clinical manifestations
in adults, the clinical signiﬁcance in children remains controversial.
In this study we investigated the incidence of HHV6 reactivation
and HCT-associated morbidity and mortality in children.
Methods: Between 1/2004 and 4/2006 59 patients, median age
6.6y (0.1-18.1), underwent 68 allogeneic HCTs. By quantitative
PCR HHV6, EBV, CMV and adenovirus (AdV)-plasma loads were
measured once a week. Clinical features, engraftment, number of
transfusions, HCT-associated mortality and morbidity (like
GvHD) were monitored. Antiviral treatment for HHV-6 reactiva-
tion was only given from 4/2005 for those with clinical symptoms
assumed to be associated with HHV6. HHV6 reactivations were
grouped in group I (no HHV6), group II (loads 1000cp/mL) and
group III (loads1000cp/mL). CMV, EBV and AdV-reactivations
were treated according to local guidelines. A risk factor analyses
was performed using logistic regression.
Results: 36 HLA-id and 23 HLA non-id grafts were used: 44
bone marrow/PBSCs and 15 cord blood grafts. Median follow up
was 17 (5-35)mths. HHV6 reactivation occurred in 40/59 (67%)
with 33/40 (82%) occurring within the ﬁrst 30 d post-HCT. 23/59
(39%) had HHV6 loads above 1000cp/mL (group III). Groups did
not differ regarding sex, age, donor source or HLA-disparity. In
multivariate analysis HHV6 reactivation was associated with a
lower survival in group III (OR 0,16; range 0,03-0,89; p0.035) as
well as with more multiple viral reactivations (p0,049: OR 5,5;
range 1,1-29) were seen in this group. In 11/13 multiple viral
reactivation HHV6 was the ﬁrst viral reactivation. There was a
non-signiﬁcant trend for more grade 2-4 acute-GvHD (p0,058
OR 4,3; range 0,8-18) in group III. HHV6 didnot inﬂuence period
of neutro-trombocytopenia.
Conclusion: HHV6 reactivation is common after HCT in chil-
dren and is associated with a higher rate of multiple viral reacti-
vations, aGvHD and with a lower survival rate. Although the exact
role of HHV6 reactivation in transplantation associated morbidity
and mortality has to be elucidated, early detection and initiation of
therapy might inﬂuence the outcome.
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JOB SATISFACTION AMONG ADVANCED PRACTICE NURSES WITHIN
THE PEDIATRIC BLOOD AND MARROW TRANSPLANT CONSORTIUM
Browning, B.1, Thormann, K.1, Coyne, K.1, Halverson, T.1, The Pedi-
atric Blood and Marrow Transplant Consortium Nursing Discipline.2
1Children’s Memorial Hospital, Chicago, IL; 2Pediatric Blood and Mar-
row Transplant Consortium.
Introduction:
Advanced Practice Stem Cell Transplant (SCT) Nursing pro-
vides unique challenges associated with the medical science of
SCT, current healthcare environment and intense relationships
with patients and families due to the demanding nature of this
therapy. Although job satisfaction among nurses has been discussed
in the literature, the focus has been on work related and psycho-
logical stresses of SCT staff nurses working in inpatient SCT units
1,2. To date little if any research has been done exploring job
satisfaction speciﬁc to Advanced Practice SCT Nurses (APSCTN)
who have become integral members of the pediatric SCT team.
Methods:
Pediatric Blood and Marrow Transplant Consortium (PBMTC)
Nursing Discipline members completed a simple questionnaire
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